CO2020009225A2 - Análogos de dihidrobenzofurano e indeno como inhibidores del sarcómero cardíaco - Google Patents
Análogos de dihidrobenzofurano e indeno como inhibidores del sarcómero cardíacoInfo
- Publication number
- CO2020009225A2 CO2020009225A2 CONC2020/0009225A CO2020009225A CO2020009225A2 CO 2020009225 A2 CO2020009225 A2 CO 2020009225A2 CO 2020009225 A CO2020009225 A CO 2020009225A CO 2020009225 A2 CO2020009225 A2 CO 2020009225A2
- Authority
- CO
- Colombia
- Prior art keywords
- dihydrobenzofuran
- cardiac sarcomere
- pharmaceutically acceptable
- indene analogs
- inhibitors
- Prior art date
Links
- 230000000747 cardiac effect Effects 0.000 title abstract 2
- 210000002235 sarcomere Anatomy 0.000 title abstract 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 title 2
- 125000003454 indenyl group Chemical class C1(C=CC2=CC=CC=C12)* 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000019622 heart disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se proporcionan compuestos de fórmula (I), o una sal farmacéuticamente aceptable de este, en donde A, Z, B, R1, R2, R3, G1, G2 y G3 son como se define en la presente. También se proporciona una composición farmacéuticamente aceptable que comprende un compuesto de fórmula (I) o una sal farmacéuticamente aceptable de este. También se proporcionan métodos para utilizar un compuesto de fórmula (I), o una sal farmacéuticamente aceptable de este para uso en métodos de tratamiento de enfermedades del corazón a través de la inhibición del sarcómero cardíaco.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862619643P | 2018-01-19 | 2018-01-19 | |
US201862745724P | 2018-10-15 | 2018-10-15 | |
PCT/US2019/014344 WO2019144041A1 (en) | 2018-01-19 | 2019-01-18 | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020009225A2 true CO2020009225A2 (es) | 2020-08-10 |
Family
ID=65324663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0009225A CO2020009225A2 (es) | 2018-01-19 | 2020-07-27 | Análogos de dihidrobenzofurano e indeno como inhibidores del sarcómero cardíaco |
Country Status (20)
Country | Link |
---|---|
US (3) | US10836755B2 (es) |
EP (1) | EP3740481B1 (es) |
JP (2) | JP7401439B2 (es) |
KR (1) | KR20200112895A (es) |
CN (3) | CN117964573A (es) |
AU (1) | AU2019208331B2 (es) |
BR (1) | BR112020014428A2 (es) |
CA (1) | CA3087283A1 (es) |
CL (2) | CL2020001871A1 (es) |
CO (1) | CO2020009225A2 (es) |
DK (1) | DK3740481T3 (es) |
EC (1) | ECSP20044709A (es) |
IL (1) | IL276094B2 (es) |
MA (1) | MA51620A (es) |
MX (2) | MX2020007532A (es) |
PH (1) | PH12020551090A1 (es) |
SG (1) | SG11202006296YA (es) |
TW (1) | TWI835770B (es) |
UY (1) | UY38057A (es) |
WO (1) | WO2019144041A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA51620A (fr) | 2018-01-19 | 2020-11-25 | Cytokinetics Inc | Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques |
EP3814343B1 (en) * | 2018-06-26 | 2023-01-11 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
US11964967B2 (en) * | 2018-06-26 | 2024-04-23 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
BR112021003496A2 (pt) | 2018-08-31 | 2021-05-18 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para tratar doença cardíaca, para tratar uma doença ou afecção associada à cardiomiopatia hipertrófica, ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, ou afecção que está associada à pequena cavidade do ventículo esquerdo e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, ou afecção selecionada dentre distrofias musculares e doenças de armazenamento de glicogênio, para inibir o sarcômero cardíaco |
KR20220016469A (ko) * | 2019-05-03 | 2022-02-09 | 프락시스 프리시젼 메디신즈, 인크. | Kcnt1 억제제 및 사용 방법 |
KR20220082803A (ko) * | 2019-07-17 | 2022-06-17 | 싸이토키네틱스, 인코포레이티드 | (r)-n-(5-(5-이소프로필-1,2,4-옥사디아졸-3-일)-2,3-디하이드로-1h-인덴-1-일)-2-메틸-2h-테트라졸-5-카르복사미드의 다형체들 |
BR112022000494A2 (pt) * | 2019-07-17 | 2022-03-03 | Cytokinetics Inc | Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica |
DK3999038T3 (da) | 2019-07-17 | 2024-03-18 | Cytokinetics Inc | Orale formuleringer af en kardial sarcomer-inhibitor |
CN112094253B (zh) * | 2020-09-10 | 2023-01-10 | 株式会社大熊制药 | 用于制备sglt抑制剂中间体的合成方法 |
CA3209557A1 (en) | 2021-03-04 | 2022-09-09 | Bradley P. Morgan | Cardiac sarcomere inhibitors |
CA3225787A1 (en) * | 2021-07-16 | 2023-01-19 | Cytokinetics, Inc. | Methods for treating hypertrophic cardiomyopathy |
CN117813304A (zh) | 2021-08-03 | 2024-04-02 | 赛特凯恩蒂克公司 | 用于制备阿夫凯泰的方法 |
WO2023211872A1 (en) | 2022-04-26 | 2023-11-02 | MyoKardia, Inc. | Methods of administering myosin inhibitors |
US20240091203A1 (en) | 2022-07-20 | 2024-03-21 | Cytokinetics, Incorporated | Methods for treating non-obstructive hypertrophic cardiomyopathy |
US20240115554A1 (en) | 2022-08-04 | 2024-04-11 | Cytokinetics, Incorporated | Methods for treating obstructive hypertrophic cardiomyopathy |
WO2024040190A1 (en) | 2022-08-18 | 2024-02-22 | Cytokinetics, Incorporated | Indane and coumaran derivatives as fast skeletal muscle myosin inhibitors |
WO2024134498A1 (en) | 2022-12-22 | 2024-06-27 | Assia Chemical Industries Ltd. | Solid state forms of aficamten and process for preparation thereof |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US633499A (en) | 1899-06-29 | 1899-09-19 | Oil Well Supply Co | Coupling for pipes, tubes, or casings. |
DE69535592T2 (de) | 1994-03-25 | 2008-06-12 | Isotechnika, Inc., Edmonton | Verbesserung der effektivität von arzneimitteln duren deuterierung |
US6334997B1 (en) * | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
US5919785A (en) | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US20030158186A1 (en) | 2001-12-21 | 2003-08-21 | Fady Malik | Compositions and methods for treating heart failure |
WO2004064730A2 (en) * | 2003-01-14 | 2004-08-05 | Cytokinetics, Inc. | Compounds, compositions and methods |
WO2004086865A1 (en) | 2003-03-27 | 2004-10-14 | Cytokinetics, Inc. | Compounds, compositions and methods |
JP2007516176A (ja) | 2003-06-20 | 2007-06-21 | アムジエン・インコーポレーテツド | ピペラジン誘導体及び使用方法 |
MXPA06014495A (es) * | 2004-06-17 | 2007-03-01 | Cytokinetics Inc | Compuestos, composiciones y metodos. |
US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
CA2604916A1 (en) | 2005-04-22 | 2006-11-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
US20090192168A1 (en) | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
US20110275673A1 (en) * | 2008-09-19 | 2011-11-10 | Yibin Xiang | Inhibitors of sphingosine kinase 1 |
WO2010130796A1 (en) | 2009-05-15 | 2010-11-18 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
US8592426B2 (en) * | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
EA024204B1 (ru) | 2012-01-20 | 2016-08-31 | Актелион Фармасьютиклз Лтд. | Производные гетероциклических амидов в качестве антагонистов p2xрецептора |
LT3010910T (lt) | 2013-06-21 | 2020-03-10 | MyoKardia, Inc. | Pirimidindiono junginiai, skirti širdies ligoms |
US9199945B2 (en) | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
US9663516B2 (en) | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
CN111393414B (zh) | 2015-01-22 | 2024-05-07 | 迈奥卡迪亚公司 | 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物 |
US20180368410A1 (en) | 2015-12-17 | 2018-12-27 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
US20190364899A1 (en) | 2015-12-18 | 2019-12-05 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
EP3448519A4 (en) | 2016-04-29 | 2020-01-22 | Board Of Regents, The University Of Texas System | SIGMA RECEIVER BINDERS |
US11066396B2 (en) | 2016-06-23 | 2021-07-20 | Merck Sharp & Dohme Corp. | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors |
EA038627B1 (ru) | 2016-09-27 | 2021-09-24 | Мерк Шарп И Доум Корп. | ПРОИЗВОДНЫЕ ХРОМАНА, ИЗОХРОМАНА И ДИГИДРОИЗОБЕНЗОФУРАНА В КАЧЕСТВЕ НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2, ИХ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ |
WO2018089433A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
WO2018156883A1 (en) | 2017-02-23 | 2018-08-30 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
JP2020529996A (ja) | 2017-08-04 | 2020-10-15 | マイオカーディア,インク | 肥大型心筋症の治療で使用するためのマバカムテン |
MA51620A (fr) | 2018-01-19 | 2020-11-25 | Cytokinetics Inc | Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques |
PT3762368T (pt) | 2018-03-08 | 2022-05-06 | Incyte Corp | Compostos de aminopirazina diol como inibidores de pi3k-y |
US11964967B2 (en) | 2018-06-26 | 2024-04-23 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
EP3814343B1 (en) | 2018-06-26 | 2023-01-11 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
BR112021003496A2 (pt) | 2018-08-31 | 2021-05-18 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para tratar doença cardíaca, para tratar uma doença ou afecção associada à cardiomiopatia hipertrófica, ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, ou afecção que está associada à pequena cavidade do ventículo esquerdo e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, ou afecção selecionada dentre distrofias musculares e doenças de armazenamento de glicogênio, para inibir o sarcômero cardíaco |
KR20230079053A (ko) | 2020-08-28 | 2023-06-05 | 미요카디아, 인크. | 미오신 조절제를 이용한 치료 방법 |
-
2019
- 2019-01-18 MA MA051620A patent/MA51620A/fr unknown
- 2019-01-18 JP JP2020539814A patent/JP7401439B2/ja active Active
- 2019-01-18 CN CN202311746655.9A patent/CN117964573A/zh active Pending
- 2019-01-18 BR BR112020014428-2A patent/BR112020014428A2/pt unknown
- 2019-01-18 EP EP19703917.5A patent/EP3740481B1/en active Active
- 2019-01-18 UY UY38057A patent/UY38057A/es unknown
- 2019-01-18 TW TW108101933A patent/TWI835770B/zh active
- 2019-01-18 WO PCT/US2019/014344 patent/WO2019144041A1/en unknown
- 2019-01-18 CN CN202311746636.6A patent/CN117924208A/zh active Pending
- 2019-01-18 MX MX2020007532A patent/MX2020007532A/es unknown
- 2019-01-18 SG SG11202006296YA patent/SG11202006296YA/en unknown
- 2019-01-18 DK DK19703917.5T patent/DK3740481T3/da active
- 2019-01-18 US US16/252,483 patent/US10836755B2/en active Active
- 2019-01-18 CN CN201980009128.5A patent/CN111757875B/zh active Active
- 2019-01-18 KR KR1020207023807A patent/KR20200112895A/ko not_active Application Discontinuation
- 2019-01-18 CA CA3087283A patent/CA3087283A1/en active Pending
- 2019-01-18 AU AU2019208331A patent/AU2019208331B2/en active Active
-
2020
- 2020-07-14 MX MX2022014312A patent/MX2022014312A/es unknown
- 2020-07-14 CL CL2020001871A patent/CL2020001871A1/es unknown
- 2020-07-16 PH PH12020551090A patent/PH12020551090A1/en unknown
- 2020-07-16 IL IL276094A patent/IL276094B2/en unknown
- 2020-07-27 CO CONC2020/0009225A patent/CO2020009225A2/es unknown
- 2020-07-31 EC ECSENADI202044709A patent/ECSP20044709A/es unknown
- 2020-09-04 US US17/013,472 patent/US11472796B2/en active Active
-
2022
- 2022-04-28 CL CL2022001091A patent/CL2022001091A1/es unknown
- 2022-08-31 US US17/823,910 patent/US20230119665A1/en active Pending
-
2023
- 2023-09-26 JP JP2023163639A patent/JP2023169374A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020009225A2 (es) | Análogos de dihidrobenzofurano e indeno como inhibidores del sarcómero cardíaco | |
AR122783A2 (es) | Inhibidores de kras g12c y métodos para su uso | |
ECSP24026637A (es) | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona | |
AR116283A1 (es) | Inhibidores del sarcómero cardíaco | |
CL2022003434A1 (es) | Compuestos para tratar la enfermedad de huntington (divisional solicitud 202003378) | |
AR120700A1 (es) | Inhibidores de kras g12c | |
CL2022001739A1 (es) | Compuestos tricíclicos sustituidos | |
CL2020003131A1 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
ECSP22019360A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos | |
AR108711A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
CO2017009891A2 (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
EA202193015A1 (ru) | Ингибиторы cdk | |
UY28192A1 (es) | Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan. | |
EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
BR112021022536A2 (pt) | Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo | |
CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
CL2019002220A1 (es) | Gasotransmisor electroquímico que genera composiciones y métodos de uso de los mismos y apósitos y sistemas de tratamiento que incorpora los mismos. | |
CO2021010512A2 (es) | Compuesto heterociclo pentacíclico | |
CO2022006942A2 (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
AR114263A1 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
CL2022001353A1 (es) | Inhibidores de egfr | |
EA202091733A1 (ru) | Аналоги дигидробензофурана и индена в качестве ингибиторов саркомера сердца | |
CO2021010415A2 (es) | Inhibidor jak y método de preparación del mismo |